Oncoinvent ASA (CHIX:ONCINO) Beneish M-Score: 2.93 (As of Jun. 27, 2026)


CHIX:ONCINO Oncoinvent ASA CHIX:ONCINO
36 GF Score
Price kr1,039.91
GF Value kr20,399.27
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Beneish M-Score?

Oncoinvent ASA CHIX:ONCINO 36 Beneish M-Score is 2.93 as of Jun. 27, 2026. GuruFocus rates CHIX:ONCINO with a GF Score™ of 36/100 and a GF Value™ of kr20,399.27. The stock has 4 warning signs investors should review. Among 831 Biotechnology companies, Oncoinvent ASA ranks worse than 90.37% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 2.93 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Oncoinvent ASA's Beneish M-Score or its related term are showing as below:

CHIX:ONCINo' s Beneish M-Score Range Over the Past 10 Years
Min: -2.94   Med: 0   Max: 2.93
Current: 2.93

During the past 11 years, the highest Beneish M-Score of Oncoinvent ASA was 2.93. The lowest was -2.94. And the median was 0.00.


Oncoinvent ASA Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA Beneish M-Score Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.94 0.00 0.00 0.00 2.93

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.93

CHIX:ONCINO vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Oncoinvent ASA's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncoinvent ASA Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Oncoinvent ASA's Beneish M-Score falls into.


CHIX:ONCINO
36GF Score
Oncoinvent ASA CHIX:ONCINO
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Oncoinvent ASA for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1233+0.528 * 1+0.404 * 0.85+0.892 * 8.4416+0.115 * 0.8412
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.0899+4.679 * -0.122942-0.327 * 0.7805
=2.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was kr6.06 Mil.
Revenue was kr23.04 Mil.
Gross Profit was kr23.04 Mil.
Total Current Assets was kr187.31 Mil.
Total Assets was kr204.96 Mil.
Property, Plant and Equipment(Net PPE) was kr15.58 Mil.
Depreciation, Depletion and Amortization(DDA) was kr11.25 Mil.
Selling, General, & Admin. Expense(SGA) was kr6.35 Mil.
Total Current Liabilities was kr57.96 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.68 Mil.
Net Income was kr-155.07 Mil.
Gross Profit was kr0.00 Mil.
Cash Flow from Operations was kr-129.87 Mil.
Total Receivables was kr5.82 Mil.
Revenue was kr2.73 Mil.
Gross Profit was kr2.73 Mil.
Total Current Assets was kr142.28 Mil.
Total Assets was kr171.02 Mil.
Property, Plant and Equipment(Net PPE) was kr26.71 Mil.
Depreciation, Depletion and Amortization(DDA) was kr14.56 Mil.
Selling, General, & Admin. Expense(SGA) was kr8.36 Mil.
Total Current Liabilities was kr57.94 Mil.
Long-Term Debt & Capital Lease Obligation was kr4.74 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6.061 / 23.037) / (5.824 / 2.729)
=0.263098 / 2.134115
=0.1233

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.729 / 2.729) / (23.037 / 23.037)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (187.311 + 15.581) / 204.958) / (1 - (142.277 + 26.71) / 171.015)
=0.01008 / 0.011859
=0.85

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=23.037 / 2.729
=8.4416

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(14.555 / (14.555 + 26.71)) / (11.25 / (11.25 + 15.581))
=0.35272 / 0.419291
=0.8412

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6.348 / 23.037) / (8.362 / 2.729)
=0.275557 / 3.064126
=0.0899

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.675 + 57.959) / 204.958) / ((4.742 + 57.939) / 171.015)
=0.286078 / 0.366523
=0.7805

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-155.07 - 0 - -129.872) / 204.958
=-0.122942

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Oncoinvent ASA has a M-score of 2.93 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 2.93 mean?
Oncoinvent ASA (CHIX:ONCINO) has a Beneish M-Score of 2.93 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Oncoinvent ASA and its competitors. According to the industry distribution chart, Oncoinvent ASA ranks #751 out of 831 companies in the Biotechnology industry, placing it in the top 90.4%.
Is Oncoinvent ASA's Beneish M-Score too high?
Oncoinvent ASA's current Beneish M-Score is 2.93. Based on the distribution chart, Oncoinvent ASA ranks #751 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #751 out of 831 companies for Beneish M-Score. This places Oncoinvent ASA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Beneish M-Score is 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Beneish M-Score of 2.93. The stock's GF Value™ is kr20,399.27, compared to a current price of kr1,039.91 — trading 94.9% below its estimated fair value. The current Beneish M-Score is 2.93. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Beneish M-Score is 2.93 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr1,039.91 is trading 94.9% below its estimated GF Value™ of kr20,399.27.

Key valuation signals for CHIX:ONCINO:

  • Beneish M-Score: 2.93
  • GF Value™: kr20,399.27 vs. price of kr1,039.91 (94.9% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for CHIX:ONCINO

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,039.91
Price
kr20,399.27
GF Value